{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:26:30Z","timestamp":1759937190182,"version":"3.41.2"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Severe community-acquired pneumonia (sCAP) is one of the major diseases within the ICU. We hypothesize that subtyping sCAP based on simple inflammatory markers, organ dysfunction, and clinical metagenomics results is feasible.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>In this study, we retrospectively enrolled immunocompetent sCAP patients requiring invasive mechanical ventilation, who underwent clinical metagenomics from 17 medical centers. We collected data on potentially pathogenic species reported by clinical metagenomics and clinical information for all patients. Latent class analysis (LCA) was applied to routine clinical parameters such as gender, age, white blood cell (WBC), lymphocytes, C-reactive protein (CRP), and Procalcitonin (PCT), identifying two optimally fitting models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 569 patients were enrolled. Compared to class B, class A was characterized by a younger age, higher CRP and PCT levels, and a higher incidence of coagulation dysfunction, liver failure, circulatory failure, and renal failure. However, the mortality rates were similar between the two groups. In class A, more cases of <jats:italic>Streptococcus<\/jats:italic> spp. and fewer cases of HSV-1 and <jats:italic>Candida<\/jats:italic> spp. were detected. Among the patients in the two phenotypes, 48.7% and 57.5% received corticosteroid treatment, respectively. In the class A, corticosteroid treatment was not associated with patient mortality (unadjusted hazard ratio (HR)=0.988; 95% confidence interval (CI), 0.634\u20131.541; p=0.959). In contrast, in the class B group, the use of corticosteroids was associated with a reduced mortality rate (adjusted HR=0.719; 95% CI, 0.525\u20130.986; p=0.04). Additional analysis showed that in class B, methylprednisolone was associated with reduced mortality (adjusted HR=0.61; 95% CI, 0.44\u20130.86; p=0.005), while dexamethasone was not associated with mortality (adjusted HR=1.4; 95% CI, 0.89\u20132.22; p=0.148). In addition, after dose conversion, the results showed that higher doses of corticosteroids in class B were associated with increased mortality (adjusted HR=1.01; 95% CI, 1.00\u20131.01; p=0.005).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We identified two classes based on clinical metagenomics and clinical features. Class B exhibited a better response to corticosteroid compared to class A. The rapid identification of these phenotypes could facilitate the screening of sCAP patients responsive to corticosteroid in future prospective clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2024.1516620","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T06:43:26Z","timestamp":1736232206000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Identifying subgroup of severe community-acquired pneumonia based on clinical metagenomics, a multicenter retrospective cohort study"],"prefix":"10.3389","volume":"14","author":[{"given":"Mingqiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanzhang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1164\/rccm.201807-1419OC","article-title":"Transcriptomic signatures in sepsis and a differential response to steroids. From the VANISH randomized trial","volume":"199","author":"Antcliffe","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0140-6736(14)62447-8","article-title":"Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"385","author":"Blum","year":"2015","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","article-title":"Hydrocortisone in severe community-Acquired pneumonia","volume":"388","author":"Dequin","year":"2023","journal-title":"N Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/NEJMcp2303286","article-title":"Community-acquired pneumonia","volume":"389","author":"File","year":"2023","journal-title":"N Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/s13054-022-04251-2","article-title":"Latent class analysis of imaging and clinical respiratory parameters from patients with COVID-19-related ARDS identifies recruitment subphenotypes","volume":"26","author":"Filippini","year":"2022","journal-title":"Crit. Care"},{"key":"B6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12890-022-02300-8","article-title":"Risk factors associated with Pneumocystis jirovecii pneumonia in non-HIV immunocompromised patients and co-pathogens analysis by metagenomic next-generation sequencing","volume":"23","author":"Huang","year":"2023","journal-title":"BMC pulmonary Med."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.618830","article-title":"Case report: epstein-barr virus encephalitis complicated with brain stem hemorrhage in an immune-competent adult","volume":"12","author":"Huang","year":"2021","journal-title":"Front. Immunol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28337","article-title":"Viral reactivation in the lungs of patients with severe pneumonia is associated with increased mortality, a multicenter, retrospective study","volume":"95","author":"Huang","year":"2023","journal-title":"J. Med. Virol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.07.140","article-title":"Clinical characteristics and prognosis of patients with severe pneumonia with pneumocystis jirovecii colonization: A multicenter, retrospective study","volume":"23","author":"Jiang","year":"2024","journal-title":"Chest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","author":"Mandell","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13054-023-04347-3","article-title":"Severe community-acquired Streptococcus pneumoniae bacterial meningitis: clinical and prognostic picture from the intensive care unit","volume":"27","author":"Martin-Cerezuela","year":"2023","journal-title":"Crit. Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00134-023-07033-8","article-title":"ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia","volume":"49","author":"Martin-Loeches","year":"2023","journal-title":"Intensive Care Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s00134-022-06684-3","article-title":"Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia","volume":"48","author":"Meduri","year":"2022","journal-title":"Intensive Care Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2101856","DOI":"10.1183\/13993003.01856-2021","article-title":"Blood leukocyte transcriptomes in Gram-positive and Gram-negative community-acquired pneumonia","volume":"59","author":"Pereverzeva","year":"2022","journal-title":"Eur. Respir. J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00134-022-06699-w","article-title":"Corticosteroids for severe community-acquired pneumonia: a story without an ending","volume":"48","author":"Rochwerg","year":"2022","journal-title":"Intensive Care Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1164\/rccm.200905-0808OC","article-title":"Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial","volume":"181","author":"Snijders","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13054-022-03972-8","article-title":"Identifying clinical subtypes in sepsis-survivors with different one-year outcomes: a secondary latent class analysis of the FROG-ICU cohort","volume":"26","author":"Soussi","year":"2022","journal-title":"Crit. Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.v3.4","article-title":"MASS cohort: Multicenter, longitudinal, and prospective study of the role of microbiome in severe pneumonia and host susceptibility","volume":"3","author":"Wei","year":"2024","journal-title":"Imeta"},{"key":"B19","doi-asserted-by":"publisher","first-page":"106195","DOI":"10.1016\/j.jinf.2024.106195","article-title":"Landscape of fungal detection in the lungs of patients with severe pneumonia in the ICU, a multicenter study based on clinical metagenomics","volume":"89","author":"Wei","year":"2024","journal-title":"J. Infect."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1183\/13993003.00474-2016","article-title":"Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia","volume":"48","author":"Wirz","year":"2016","journal-title":"Eur. Respir. J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13054-023-04561-z","article-title":"Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Wu","year":"2023","journal-title":"Crit. Care"},{"key":"B22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s13054-023-04530-6","article-title":"Incidence and clinical features of HHV-7 detection in lower respiratory tract in patients with severe pneumonia: a multicenter, retrospective study","volume":"27","author":"Xu","year":"2023","journal-title":"Crit. Care (London England)"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1516620\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T06:43:29Z","timestamp":1736232209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1516620\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":22,"alternative-id":["10.3389\/fcimb.2024.1516620"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2024.1516620","relation":{},"ISSN":["2235-2988"],"issn-type":[{"type":"electronic","value":"2235-2988"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"article-number":"1516620"}}